Yizhou Jiang

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

Sattva S. Neelapu, Frederick L. Locke, Nancy L. Bartlett et al. · New England Journal of Medicine · 2017 · 5.9K citations · Full text

Medicine, Hematology, Oncology +16

Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial

Frederick L. Locke, Armin Ghobadi, Caron A. Jacobson et al. · The Lancet Oncology · 2018 · 2.3K citations

Medicine, Oncology, Pharmacology +12

Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma

Frederick L. Locke, Sattva S. Neelapu, Nancy L. Bartlett et al. · Molecular Therapy · 2017 · 619 citations · Full text

Medicine, Immunology, Oncology +17

Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study

Timothy Iveson, Ross C. Donehower, S. Tjulandin et al. · The Lancet Oncology · 2014 · 261 citations

Medicine, Oncology, Pharmacology +15

Preliminary Results of Prophylactic Tocilizumab after Axicabtageneciloleucel (axi-cel; KTE-C19) Treatment for Patients with Refractory,Aggressive Non-Hodgkin Lymphoma (NHL)

Frederick L. Locke, Sattva S. Neelapu, Nancy L. Bartlett et al. · Blood · 2017 · 181 citations

Medicine, Oncology, Pharmacology +14